Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register

The objective of this study was to compare the efficacy and safety of rituximab in older vs younger patients with rheumatoid arthritis. Data on 367 patients with rheumatoid arthritis treated with rituximab in the Norwegian Disease-Modifying Antirheumatic Drug (NOR-DMARD) register were analysed, comparing patients aged ≥ 65 years (n = 91) with patients aged